Inventor · disambiguated record
Defne Yarar
Also filed as: YARAR DEFNE
3 granted patents·6 pending applications·8 citations·filing 2015–2023
63Inventor score
Files withMERRIMACK PHARMACEUTICALS INC3SQZ BIOTECHNOLOGIES CO3STEMCELL TECHNOLOGIES CANADA INC2FLAGSHIP PIONEERING INNOVATIONS V INC1
Top patents by PatentIndex Score
9 records- 0184US9688761B2Biomarker profiles for predicting outcomes of cancer therapy with ERBB3 inhibitors and/or chemotherapiesMERRIMACK PHARMACEUTICALS INC·Filed 2015·Granted Jun 27, 2017·4 cites·24 claims
- 0283US11692168B2Delivery of biomolecules to PBMCs to modify an immune responseSQZ BIOTECHNOLOGIES CO·Filed 2020·Granted Jul 4, 2023·3 cites·38 claims
- 0374US10273304B2Biomarker profiles for predicting outcomes of cancer therapy with ERBB3 inhibitors and/or chemotherapiesMERRIMACK PHARMACEUTICALS INC·Filed 2017·Granted Apr 30, 2019·1 cites·36 claims
- 0462US2024228956A9DELIVERY OF BIOMOLECULES TO PBMCs TO MODIFY AN IMMUNE RESPONSESQZ BIOTECHNOLOGIES CO·Filed 2023·Application pending·0 cites
- 0555US2017210810A1Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapiesMERRIMACK PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 0652US2025255961A1Methods to stimulate immune responses to mutant ras using nucleated cellsSTEMCELL TECHNOLOGIES CANADA INC·Filed 2021·Application pending·0 cites
- 0749US2022233676A1Formulations of activating antigen carriersSQZ BIOTECHNOLOGIES CO·Filed 2021·Application pending·0 cites
- 0847US2025269001A1Methods to stimulate immune responses to mutant ras using anucleate cellsSTEMCELL TECHNOLOGIES CANADA INC·Filed 2021·Application pending·0 cites
- 0946US2024132559A1Compositions and methods for modulating myc expressionFLAGSHIP PIONEERING INNOVATIONS V INC·Filed 2021·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Defne Yarar files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →